p16甲基化meta分析.pdfVIP

The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis 1. 2. 1 3 1 1 Xiang-Bin Xing , Wei-Bin Cai , Liang Luo , Long-Shan Liu , Hui-Juan Shi , Min-Hu Chen * 1 Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2 Department of Biochemistry, Zhongshan Medical School, Sun Yat-sen University, Guangzhou, China, 3 Laboratory of General Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China Abstract Background: The prognostic value of p16 promoter hypermethylation in cancers has been evaluated for several years while the results remain controversial. We thus performed a systematic review and meta-analysis of studies assessing the impact of p16 methylation on overall survival (OS) and disease-free survival (DFS) to clarify this issue. Methods: We searched Pubmed, Embase and ISI web of knowledge to identify studies on the prognostic impact of p16 hypermethylation in cancers. A total of 6589 patients from 45 eligible studies were included in the analysis. Pooled hazard ratios (HRs) with 95% confidence interval (95% CI) were calculated to estimate the effect using random-effects model. Results: The analysis indicated that p16 hypermethylation had significant association with poor OS of non-small cell lung cancer (NSCLC) (HR 1.74, 95% CI: 1.36–2.22) and colorectal cancer (CRC) (HR 1.80; 95% CI 1.27–2.55). Moreover, the significant correlation was present between p16 hypermethylation and DFS of NSCLC (HR 2.04, 95% CI: 1.19–3.50) and head and neck cancer (HR 2.24, 95% CI: 1.35–3.73). Additionally, in the analysis of the studies following REMARK guidelines more rigorously, p16 hypermethylation had unfavorable impact on OS of NSCLC (